Law360 (March 11, 2021, 3:58 PM EST) — A Pennsylvania dermatology business says that after it spent $1 million to license an injectable anti-aging treatment from Medinter Ltd., it was left defending an infringement suit over an unapproved drug as the British company swiftly moved to terminate the license agreement.
Malvern, Pennsylvania-based DermAvance Pharmaceuticals Inc. filed suit Wednesday, alleging Medinter repeatedly breached a 2007 deal allowing DermAvance to license a Medinter drug called Derma Veil for the U.S. market. It also asserts Medinter lied to DermAvance about the drug’s approval status in the European Union.
By the terms of that $1 million deal, DermAvance was responsible for securing approval…
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!
